Could antibody shots replace daily HIV pills for kids? new trial begins in botswana

NCT ID NCT06508749

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study in Botswana tests whether giving three powerful antibodies by infusion can help children who started HIV treatment early keep the virus suppressed without taking daily antiretroviral pills. About 41 children aged 2 to 12 will receive the antibodies while stopping their usual medication for a period. The goal is to see if the antibodies alone can control the virus and protect the immune system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: three broadly neutralizing antibodies (VRC07-523LS, PGDM1400LS, PGT121.414.LS)
What this could lead to: If it works, this could point toward a way for children with HIV to stop daily antiretroviral therapy and still keep the virus under control using periodic antibody infusions.
What could go wrong: This is an early Phase I/II trial with only 41 children, so results may not apply broadly. The antibodies may not prevent viral rebound, and some children could experience side effects or need to restart daily pills.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV HIV INFECTIONS

Contacts and locations

Locations

Botswana Harvard Health Partnership CRS (CRS #31833)
RECRUITING

Gaborone, Botswana
Francistown CRS (CRS #31891)
RECRUITING

Francistown, Botswana

More trials for these conditions

Other studies related to the condition(s) this trial covers.